{
    "clinical_study": {
        "@rank": "57206", 
        "arm_group": [
            {
                "arm_group_label": "HRV Group", 
                "description": "Subjects who had received 2 doses of HRV vaccine in previous studies."
            }, 
            {
                "arm_group_label": "Placebo Group", 
                "description": "Subjects who had received 2 doses of placebo in previous studies."
            }
        ], 
        "biospec_descr": {
            "textblock": "Serum samples"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "This study aims to evaluate the serologic response to PCV-1 in the serum samples previously\n      collected during initiation of vaccination series of Human Rotavirus (HRV) vaccine studies\n      (1-2 months post Dose 2 of HRV vaccine or placebo). Additionally, pre-vaccination sera\n      samples from any infants testing positive for PCV-1 antibodies at the post-vaccination time\n      point will also be evaluated."
        }, 
        "brief_title": "Serologic Response to Porcine Circovirus Type 1 (PCV-1) in Infants Following Administration of Rotarix\u2122", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Infections, Rotavirus", 
        "condition_browse": {
            "mesh_term": "Rotavirus Infections"
        }, 
        "detailed_description": {
            "textblock": "Serum samples collected from 6 clinical trials previously conducted for HRV vaccine\n      (Rotarix\u2122) are used in this study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Not applicable as no subjects will be actively enrolled in this study, only the sera\n        samples of the subjects who were a part of previously conducted trials will be used for\n        testing. However, the archived serum samples of only those subjects who satisfy the\n        following criteria will be included in this study:\n\n          -  Subjects who received two doses of HRV vaccine or Placebo and were included in the\n             ATP cohort for immunogenicity in the primary studies listed.\n\n          -  Subjects for whom their parents or Legally Acceptable Representatives (LARs) had\n             agreed that their child or wards blood samples could be used for further research\n             while giving consent for any of the primary studies listed.\n\n          -  Subjects who have sufficient residual volume of serum samples at both pre- and\n             post-vaccination time points.\n\n        Exclusion Criteria:\n\n          -  Not Applicable"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "12 Weeks", 
            "minimum_age": "6 Weeks", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Infants aged 6 to 12 weeks from 6 previously completed clinical trials, who received 2\n        doses of either Rotarix\u2122 or Placebo."
            }
        }, 
        "enrollment": {
            "#text": "1", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 15, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02153333", 
            "org_study_id": "114793", 
            "secondary_id": [
                "444563/005 (Rota-005)", 
                "444563/023 (Rota-023)", 
                "444563/028 (Rota-028)", 
                "444563/029 (Rota-029)", 
                "102247 (Rota-036)", 
                "106481 (Rota-054)"
            ]
        }, 
        "intervention": {
            "arm_group_label": [
                "HRV Group", 
                "Placebo Group"
            ], 
            "description": "Serum samples collected at pre-vaccination and at 1-2 months post Dose 2 in the previously conducted clinical trials will be assessed for anti-PCV-1 antibodies in this study.  Additionally, pre-vaccination sera samples from any infants testing positive for PCV-1 antibodies at the post-vaccination time point will also be evaluated.", 
            "intervention_name": "Serum sample", 
            "intervention_type": "Procedure"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Laboratory evaluations", 
            "Serologic response", 
            "Human rotavirus (HRV) vaccine", 
            "Porcine circovirus type 1 (PCV-1)"
        ], 
        "lastchanged_date": "May 29, 2014", 
        "number_of_groups": "2", 
        "official_title": "Blinded Retrospective Laboratory Evaluations to Assess the Serologic Response to Porcine Circovirus Type 1 (PCV-1) in Infants Following the Administration of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus Vaccine (444563)", 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Seropositivity rates for anti-PCV-1 antibodies.", 
                "safety_issue": "No", 
                "time_frame": "At 1-2 months post dose 2 of HRV vaccine or placebo."
            }, 
            {
                "measure": "Seroconversion rates for anti-PCV-1 antibodies.", 
                "safety_issue": "No", 
                "time_frame": "At 1-2 months post dose 2 of HRV vaccine or placebo."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02153333"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}